InvestorsObserver
×
News Home

Is Veru Inc (VERU) a Stock to Watch After Gaining 11.11% This Week?

Tuesday, October 17, 2023 02:12 PM | InvestorsObserver Analysts

Mentioned in this article

Is Veru Inc (VERU) a Stock to Watch After Gaining 11.11% This Week?

The market has been high on Veru Inc (VERU) stock recently. VERU gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Veru Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VERU!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With VERU Stock Today?

Veru Inc (VERU) stock is up 5.9% while the S&P 500 is down -0.29% as of 1:59 PM on Tuesday, Oct 17. VERU is higher by $0.06 from the previous closing price of $0.94 on volume of 1,907,622 shares. Over the past year the S&P 500 is up 18.57% while VERU is down -91.28%. VERU lost -$1.38 per share in the over the last 12 months. To screen for more stocks like Veru Inc click here.

More About Veru Inc

Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States. Click Here to get the full Stock Report for Veru Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App